Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)

DRUG2 trials

Sponsors

POLYSAN Scientific & Technological Pharmaceutical Company

Conditions

Diabetic NeuropathiesStroke

Phase 3

Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy

CompletedNCT04649203

POLYSAN Scientific & Technological Pharmaceutical CompanyDiabetic Neuropathies

Start: 2020-11-25End: 2021-06-06Updated: 2023-01-27

Cytoflavin in the Complex Rehabilitation of Stroke Patients

CompletedNCT05935787

POLYSAN Scientific & Technological Pharmaceutical CompanyStroke

Start: 2023-06-30End: 2024-12-07Updated: 2026-04-14

Related Papers

Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)

BMJ Open Diabetes Research & Care2022-06-0117 citations